Physician profile
Joseph Schultz
NPI 1336427210
$1,150.94
in general payments reported to CMS, 2019-2025
13 companies · $81.33 in 2025
The $81.33 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $123 · 2022: $325 · 2023: $346 · 2024: $275 · 2025: $81.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $434.57 | 2021-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $194.31 | 2022-2024 | |
| Sobi, INC | $112.81 | 2021-2024 | |
| Sanofi Pasteur INC. | $92.86 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $69.31 | 2022-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Glaxosmithkline, LLC. | $62.44 | 2024-2025 | Bexsero |
| Adlon Therapeutics L.P. | $52.40 | 2021 | |
| Boston Scientific Corporation | $28.32 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $22.66 | 2023 | |
| Ironwood Pharmaceuticals, INC | $22.05 | 2024 | |
| Seqirus USA INC | $21.22 | 2024 | Flucelvax |
| Genentech USA, INC. | $19.01 | 2021 | |
| Tris Pharma INC | $18.98 | 2024 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.